

David Sidransky, MD

Co-Founder and General Partner of Israel Biotech Fund. Dr. Sidransky is a renowned oncologist, research scientist and Professor of Oncology and Cellular & Molecular Medicine at Johns Hopkins University and Hospital. Dr. Sidransky was Vice Chairman of ImClone Systems until its acquisition by Eli Lilly for \$6.5B in 2008. He founded several biotechnology companies, including Oncormed Pharmaceuticals, (NASDAQ: OMED), a genetic testing company that was sold to Gene Logic in 1998, and Response Genetics (NASDAQ: RGDY), a developer of markers for cancer therapy.